B

iopharma can find plenty to celebrate — and a few things to despair over — in the new Republican plan to rewrite the tax code.

The long awaited “Tax Cuts and Jobs Act,” unveiled as a House bill on Thursday, will likely still be revised significantly. But so far, here are the seven provisions with the biggest implications for the drug industry:

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.